Bipolar Disorder

This report summarises what Blossom’s database shows about psychedelic and dissociative compounds in bipolar disorder, and it leads with the part that matters most: the risks. Bipolar disorder is the one population where the dominant, best-supported finding about classic psychedelics is not benefit but danger, the danger of triggering mania. The evidence for any benefit is narrow, early and confined to the lower-risk form of the illness, and the compound with the most support, ketamine, is a short-acting, closely monitored add-on rather than a cure. Read this as a map of where caution is warranted, not as encouragement.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Bipolar disorder is a serious illness that needs specialist care; its treatment, including any decision about novel or rapid-acting medicines, belongs with a psychiatrist. Classic psychedelics can destabilise mood and trigger mania in people with bipolar disorder, and they can be dangerous in combination with common medicines such as lithium. Nobody with bipolar disorder should take a psychedelic to self-treat, and the supervised trials described here are not a model for doing so at home. If you are struggling, please contact your care team or a crisis service.

A word on the numbers. Blossom tracks 125 papers and 50 trials tagged to this topic, and those counts appear on this page. The tag is leaky: most of those papers are ketamine or esketamine studies in general or treatment-resistant depression that merely include or mention bipolar patients, plus mechanism and neuroimaging work. The genuinely bipolar-specific clinical core is small, on the order of twenty studies, and the controlled trials among them are smaller still. Read the counts as breadth of coverage, not as a deep bipolar evidence base.

The central issue: manic switch

The reason this page is framed around caution is mechanistic and well documented. The serotonergic action that may lift depression can also push a bipolar brain toward mania, and sleep loss during a long psychedelic experience compounds the risk. A survey of 541 people with bipolar disorder who had taken psilocybin found about a third reported new or worsening symptoms afterwards, prominently manic symptoms, difficulty sleeping and anxiety[1]J. Psychopharmacology, bipolar survey (2022). Published case reports document manic episodes triggered by ayahuasca in bipolar disorder[2]Int. J. Bipolar Disorders, ayahuasca mania case (2015), and mania following ibogaine use even in people with no prior bipolar diagnosis[3]Am. J. Addictions, ibogaine mania cases (2015).

This is why bipolar patients are excluded from nearly every modern psychedelic-depression trial, and why a broad analysis of psychedelic adverse events found serious events concentrated in participants with pre-existing psychiatric conditions, including worsening mood, suicidal behaviour, psychosis and convulsions[4]JAMA Psychiatry, adverse-events meta-analysis (2024). The favourable safety record often quoted for psychedelics comes from carefully screened, mostly healthy or unipolar volunteers, and does not transfer to bipolar disorder.

The lithium danger

One specific interaction deserves its own warning. Lithium is a first-line, life-saving mood stabiliser, and combining it with a classic psychedelic appears to be hazardous. An analysis of online experience reports found that of 62 cases combining lithium with a psychedelic, 47% involved seizures and a further 18% involved severe adverse experiences, while none of 34 reports combining lamotrigine with a psychedelic involved seizures[5]Pharmacopsychiatry, lithium-seizure analysis (2021). The data come from unsupervised real-world use rather than a trial, but the signal is strong and biologically plausible, and it means the very medicine many people with bipolar disorder rely on makes psychedelic use markedly more dangerous.

Ketamine: the one real evidence base

Ketamine is the exception that genuinely helps, within limits. It is not a classic psychedelic but a dissociative anaesthetic, and in bipolar depression it is given as a single, monitored, rapid-acting add-on to a mood stabiliser. Two foundational randomised crossover trials at the US National Institute of Mental Health established the effect: the first (n=18) found 71% responded to ketamine versus 6% to placebo, with the difference peaking around day two[6]Arch. Gen. Psychiatry, ketamine bipolar (2010), and the second (n=15) found rapid improvement in depression and suicidal ideation within 40 minutes[7]Biological Psychiatry, Zarate ketamine bipolar (2012).

A systematic review of six studies (135 patients, all maintained on a mood stabiliser) found about 61% responded to ketamine versus 5% to placebo, and manic symptoms in only one ketamine and one placebo participant[8]Int. J. Neuropsychopharmacology review (2021), which is reassuring on switch risk in a monitored, mood-stabilised setting. The honest limit is durability: a pooled meta-analysis showed the antidepressant effect peaks at day one and loses its advantage by roughly day ten[9]Psychological Medicine meta-analysis (2016). Ketamine buys rapid, short-term relief, including from suicidal crisis, but it is an adjunct that must be repeated, not a stand-alone or lasting treatment, and esketamine’s bipolar evidence is thinner still[10]Clinical Drug Investigation, esketamine (2022).

Psilocybin in bipolar II: the cautious exception

The single piece of controlled-ish classic-psychedelic evidence is an open-label trial of a single 25 mg dose of psilocybin in bipolar II depression (n=15), which reported a large improvement, a 24-point fall in MADRS depression scores at three weeks, with 12 of 15 responding and 11 in remission, and, importantly, no manic symptoms and no rise in suicidality[11]JAMA Psychiatry, Aaronson bipolar II (2024). It was conducted with intensive psychological support, careful screening, and medications withdrawn beforehand, and it is the reason the field is willing to test this carefully at all.

It must be read with its limits in full view. It enrolled 15 people, had no control group, was conducted at a single site, and, like every psilocybin bipolar study, was restricted to bipolar II, the lower-risk form. The safety picture is also not uniform: a separate open-label bipolar II pilot saw three participants develop suicidal ideation or hypomania, which resolved with support[12]Open-label psilocybin bipolar II pilot (2025, preprint). So the most that can honestly be said is that, in the lower-risk subgroup and under intensive supervision, a single psilocybin dose showed a large antidepressant signal without clear destabilisation in one small study, and that this is a reason to run proper controlled trials, not a reason to treat.

Bipolar II is not bipolar I

A point easily lost: every scrap of classic-psychedelic clinical data in bipolar disorder is in bipolar II, and that is deliberate. Bipolar II involves hypomania, which is milder and shorter than the full mania of bipolar I, so the consequences of a switch are less catastrophic and the researchers judged the risk just acceptable enough to study. Bipolar I, the higher-risk form, has essentially no controlled psychedelic data at all, and the manic-switch concern is correspondingly greater. Any cautious optimism from the bipolar II trials should not be generalised to bipolar I, where the honest stance remains that classic psychedelics are too risky to use outside the most carefully designed research.

Monitored trial versus real life

The single most important distinction on this page is between the supervised trial and the world outside it. The encouraging psilocybin result came from a setting with weeks of screening, withdrawn medications, two therapists, an eight-hour monitored session and structured follow-up. The discouraging survey result, a third of people reporting new or worsening, often manic, symptoms, came from people taking psilocybin in ordinary life. The lithium-seizure data is entirely from unsupervised use. The same drug, the same diagnosis, very different outcomes depending on the container. For bipolar disorder more than almost any other condition, the supervision is not optional packaging around the treatment; it is most of what makes the difference between a possible benefit and a serious harm.

Reading this honestly

So where does bipolar disorder sit? It is the clearest example in this whole field of why honest framing matters. There is a real, useful, short-term role for ketamine as a monitored add-on, and there is one small, fragile, genuinely interesting signal for psilocybin in bipolar II under intensive supervision. But the loudest and best-supported message in the literature is a warning: classic psychedelics can trigger mania, they are dangerous with lithium, they are untested in bipolar I, and the favourable safety story told elsewhere does not apply here. The right posture is neither dismissal of the early ketamine and psilocybin signals nor enthusiasm that ignores the hazard, but careful, supervised, lower-risk research and, for everyone else, caution. For people living with bipolar disorder, that caution is not the field being timid. It is the field taking their safety seriously.